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Abstract Background: While dietary fat has been established as a risk factor for colorectal
cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using
Mendelian randomisation (MR), we sought to evaluate associations between polyunsaturated
(PUFA), monounsaturated (MUFA) and saturated FAs (SFAs) and CRC risk.
Methods: We analysed genotype data on 9254 CRC cases and 18,386 controls of European
ancestry. Externally weighted polygenic risk scores were generated and used to evaluate asso-
ciations with CRC per one standard deviation increase in genetically defined plasma FA levels.
Results: Risk reduction was observed for oleic and palmitoleic MUFAs (OROA Z 0.77, 95%
CI: 0.65e0.92, P Z 3.9  103; ORPOA Z 0.36, 95% CI: 0.15e0.84, P Z 0.018). PUFAs li-
noleic and arachidonic acid had negative and positive associations with CRC respectively
(ORLA Z 0.95, 95% CI: 0.93e0.98, P Z 3.7  104; ORAA Z 1.05, 95% CI: 1.02e1.07,
P Z 1.7  104). The SFA stearic acid was associated with increased CRC risk
(ORSA Z 1.17, 95% CI: 1.01e1.35, P Z 0.041).
Conclusion: Results from our analysis are broadly consistent with a pro-inflammatory FA
profile having a detrimental effect in terms of CRC risk.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Colorectal cancer (CRC) is one of the most common
cancers and a major cause of cancer-related mortality in
economically developed countries [1]. Geographical
differences in CRC incidence between countries and
migration studies have established the importance of
lifestyle and diet as major determinants for CRC risk [2].
Worldwide CRC is currently diagnosed in over one
million individuals annually; however, its incidence is set
to increase with adoption of western lifestyles in devel-
oping countries [3]. Given the importance of diet as a
risk factor for CRC, its modification offers the prospect
of impacting significantly on disease incidence through
public health initiatives.
Dietary fat has been widely implicated as a risk factor
for cancer, and meta-analyses of epidemiological studies
have tended to associate CRC risk with a higher con-
sumption of red and processed meat [4]. The association
between fat intake on cancer risk however, is likely to
depend not only on the quantity, but also on the specific
type of fatty acid (FA). Animal models and ecological
studies have tended to implicate animal fat [5], saturated
fatty acid (SFA) and certain omega-6 polyunsaturated
fatty acids (u-6 PUFAs) with an increased risk, and u-3
PUFA intake with a reduced risk [6e8]. Evidence for a
causal relationship with intake of specific types of fat
from epidemiological studies has however largely been
inconclusive. Reasons for inconsistencies in observa-
tional studies include the inherent problem of eliciting
accurate measurements of long-term diet, confounding
and reverse causation [9].
Mendelian randomisation (MR) analysis represents
an adjunct to the conventional epidemiological obser-
vational study for examining associations between an
exposure with a disease. The MR strategy makes use of
allelic variants that are randomly assigned during
meiosis and are robustly associated with traits of inter-
est, as instrumental variables (IVs). Using genetically
defined IVs as proxies of modifiable exposure avoids
confounding by environmental factors, is not subject to
reverse causality and can inform on life-long exposure
[10,11]. Since studies have shown that FA intake in-
fluences plasma levels of FAs in theory MR makes an
attractive strategy to link dietary FA to CRC risk
[12,13].
We have therefore sought to identify associations
between genetically predicted plasma PUFA, MUFAs
and SFA levels and CRC risk. Specifically: (1) the u-6
PUFAs, linoleic acid (LA), arachidonic acid (AA) and
dihomo-g-linolenic acid (DGLA); (2) the u-3 PUFAs,
eicosapentaenoic acid (EPA), docosapentaenoic acid
(DPA) and docosahexaenoic acid (DHA); (3) the
MUFAs, oleic acid (OA) and palmitoleic acid (POA);
and (4) the SFAs, palmitic acid (PA), arachidic acid and
stearic acid (SA).
2. Methods
2.1. Colorectal cancer datasets
We investigated the relationship between genetic risk
scores for levels of MUFAs, PUFAs, and SFAs and
CRC risk adopting a two-sample MR strategy using
data from seven reported genome-wide association
studies (GWAS) of CRC (Table 1). Briefly, these GWAS
were based on individuals with European ancestry:
CCFR1, CCFR2, COIN, FINLAND, UK1, Scotland1
and VQ58 [14]. Each study was approved by respective
institutional ethics review board and performed/con-
ducted in accordance with the Declaration of Helsinki.
2.2. Genotyping data
Comprehensive details of the genotyping and quality
control of the seven GWAS have been previously re-
ported [14]. Briefly, we excluded single nucleotide poly-
morphisms (SNPs) with a minor allele frequency of
<1%, low call rate <95%, those SNPs violating Har-
dyeWeinberg equilibrium, and individuals with non-
European ancestry as assessed using data from Hap-
Map v2 [15]. IMPUTEv2 software [16] was used to
recover untyped SNP genotypes using a merged refer-
ence panel consisting of Sequencing Initiative Suomi
(for the FINLAND data) or UK10K (for the remaining
data) and 1000 Genomes Project data [17,18]. Poorly
imputed SNPs, defined by an INFO score of <0.9, were
excluded. Summary statistics from the seven GWAS
were used to calculate the odds ratios (ORs) for FA-
related SNPs.
2.3. Gene variants used to construct genetic risk scores
Genetic risk scores for IVs for each plasma FA were
developed from SNPs previously identified by The Co-
horts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium. We considered
SNPs associated at genome-wide significance (i.e.
P  5.0  108) in individuals with European Ancestry.
To avoid co-linearity between SNPs for each FA we
imposed a threshold r2 value of 0.01 for linkage
disequilibrium (LD) including only the SNPs with the
strongest effect on the trait in genetic risk scores (Table
2, [19e22]). For each identified SNP, we recovered the
chromosome positions, the risk alleles, association esti-
mates and standard errors. For each SNP, the allele that
was associated with increased FA level was considered
the effect allele.
2.4. Statistical analysis
The association between the plasma level of each FA
and CRC was examined using MR on summary
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Table 1
Summary of the seven colorectal cancer genome-wide association studies.
Series Study setting Study centre Genotyping platform No. cases No. controls
CCFR1 Colon Cancer Family Registry University of Southern
California
Illumina 1M, 1M Duo 1290 1055
CCFR2 Colon Cancer Family Registry University of Southern
California
Illumina 1M, Omni express 796 2236
COIN COIN trial: Multicentre study of
cetuximab and other therapies in
metastatic CRC. Controls were unselected
blood donors
Cardiff University Affymetrix Axiom 2244 2162
FINLAND Finnish Colorectal Cancer Predisposition
Study
Helsinki University Illumina 610K/Illumina
HumanOmni2.5M
1172 8266
UK1 CORGI (colorectal Tumour Gene
Identification Consortium)
Oxford University Illumina Hap550 940 965
Scotland1 COGS (Colorectal Cancer Susceptibility
Study)
Edinburgh University Illumina Hap300/240S 1012 1012
VQ58 Cases: VICTOR, post-treatment stages of
a phase III, randomised trial of rofecoxib
(VIOXX) in patients after potentially
curative therapy. QUASAR2, multi-centre
study of capecitabine  bevacizumab as
adjuvant treatment. 1958 Birth cohort
controls
Oxford University Illumina Hap300/370,
Illumina 1M
1800 2690
Table 2
Effect sizes for plasma fatty acid content (per standard deviation increase in levels) for genome-wide significant (P < 5  108) instrumental
variables reported by CHARGE consortium.
FA subtype Fatty acid SNP ID Chr Position (bp)a Allele b StdErr P-value Variance
explainedb
SFA Arachidic acid (20:0) rs680379 20 12917400 A/G 0.098 0.01 5.81  1013 e
Palmitic acid (PA) (16:0) rs2391388 1 95485825 C/A 0.18 0.03 2.72  1011 0.21e0.98%
Stearic acid (SA) (18:0) rs6675668 1 95515637 G/T 0.17 0.02 2.16  1018 0.37e1.39%
rs11119805 1 211918244 T/A 0.17 0.03 2.8  1009 <0.01e0.72
rs102275 11 61557803 T/C 0.18 0.02 1.33  1020 0.33e1.34%
u-3 PUFA Docosahexaenoic acid
(DHA) (22:6n-3)
rs2236212 6 10995015 G/C 0.11 0.01 1.26  1015 0.7%
Docosapentaenoic acid
(DPA) (22:5n-3)
rs780094 2 27741237 T/C 0.02 0.003 9.04  1009 e
rs3734398 6 10982973 C/T 0.04 0.003 9.71  1043 8.6%
rs174547 11 61570783 T/C 0.07 0.003 3.79  10154 2.8%
Eicosapentaenoic acid
(EPA) (20:5n-3)
rs3798713 6 11008622 C/G 0.035 0.005 1.93  1012 0.4%
u-6 PUFA Arachidonic acid
(AA) (20:4n-6)
rs174547 11 61570783 T/C 1.69 0.03 3.30  10971 3.7e37.6%
rs16966952 16 15135943 G/A 0.2 0.03 2.43  1010 0.1e0.6%
Dihomo-g-linolenic acid
(DGLA) (20:3n-6)
rs174547 11 61570783 C/T 0.36 0.01 2.63  10151 8.7e11.1%
rs16966952 16 15135943 G/A 0.22 0.02 7.55  1065 2.0e4.5%
Linoleic acid (LA)
(18:2n-6)
rs10740118 10 65101207 G/C 0.25 0.04 8.08  1009 0.2e0.7%
rs174547 11 61570783 C/T 1.47 0.04 4.98  10274 7.6e18.1%
rs16966952 16 15135943 A/G 0.35 0.04 1.23  1015 0.5e2.5%
u-7 MUFA Palmitoleic acid
(POA) (16:1n-7)
rs780093 2 27742603 T/C 0.02 0.003 9.80  1010 0.23e0.93%
rs6722456 2 134529091 G/A 0.05 0.009 4.12  1008 <0.01e0.57
rs603424 10 102075479 G/A 0.03 0.004 5.69  1015 0.28e1.57%
rs11190604 10 102302457 G/A 0.02 0.004 5.69  1009 0.02e0.71%
rs102275 11 61557803 C/T 0.02 0.003 6.60  1013 0.15e1.03%
u-9 MUFA Oleic acid
(OA) (18:1n-9)
rs102275 11 61557803 C/T 0.23 0.02 2.19  1032 0.32e2.14%
FA, fatty acid; SNP, single nucleotide polymorphism; bp, base pair; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; StdErr, standard error. Effect allele influencing each FA trait is marked in bold.
a hg19 NCBI build.
b Taken from CHARGE consortium, as a percentage of total serum fatty acids, calculated by (b2*2*MAF*(1-MAF))/Var(Y) where b is the
regression coefficient, MAF is the minor allele frequency and Var(Y) is the variance in levels of the fatty acid. IVs obtained from Refs. [19,20,22].
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statistics as per Burgess (2015) [23]. The ratio estimate
ðbbÞ of all SNPs associated with each fatty acid, com-
bined, on CRC was calculated as follows:
bbZPkXkYks2YkP
kX
2
ks
2
Yk
:
where Xk corresponds to the association of SNP k (as
log of the OR per risk allele) with the fatty acid trait Y,
Yk is the association between SNP k and CRC risk (as
log of the OR) with standard error sYk . The estimate for
ðbbÞ represents the causal increase in the log odds of the
CRC, per unit change in fatty acids. The standard error
of the combined ratio estimate is given by:
se
bbZ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ1P
kX
2
ks
2
Yk
s
:
A meta-analysis of statistics for each specific FA
generated for each CRC cohort was combined under
fixed-effects models to derive the summary ORs and
confidence intervals (CIs). To assess the impact of be-
tween study heterogeneity, we also derived ORs under a
random-effects model.
A central tenet in MR is the absence of pleiotropy
(i.e. a gene influencing multiple traits) between the SNPs
influencing CRC risk and FA levels. This would be
revealed as deviation from a linear relationship between
SNPs and their effect size for any FA and CRC risk. To
examine for violation of the standard IV assumptions in
our analysis, we performed inverse variant weighted
(IVW) and MR-Egger regression tests [24].
We considered a significance level of P  0.05 as
being satisfactory to derive a conclusion. While ordi-
narily it would be appropriate to impose a Bonferroni-
corrected threshold, this assumes an independence of
IVs across all FA traits, which is not the case in the
present analysis. All statistical analyses were undertaken
using R version 3.1 software [25].
2.5. Expression quantitative trait locus analysis
To examine the relationship between SNP genotype and
expression of FA metabolism genes, we performed
expression quantitative trait locus (eQTL) analysis using
data from The Cancer Genome Atlas (TCGA) and the
genotype tissue expression (GTEx)project [26,27].
3. Results
The FA-associated genetic variants and their GWAS-
reported characteristics that were used to derive IVs for
FAs are detailed in Table 2. A reduced risk of CRC was
observed for genetic variants associated with increases in
the MUFAs studied (Table 3). In all but one of the seven
cohorts increased levels of OA were associated with
reduced CRC risk (Fig. 1). In the meta-analysis of these
seven cohorts the OROA was 0.77 (95% CI: 0.65e0.92,
P Z 3.9  103) with little evidence of between-study
heterogeneity (Phet Z 0.23, I
2 Z 26%). Similarly,
increased levels of POA were associated with reduced
CRC risk with an ORPOA of 0.36 (95% CI: 0.15e0.84,
P Z 0.018, Phet Z 0.08, I
2 Z 47%; Fig. 1).
The u-6 PUFAs LA and AA both showed associa-
tion with CRC risk, but in different directions. Specif-
ically, LA was associated with reduced risk
(ORLA Z 0.95, 95% CI: 0.93e0.98, P Z 3.7  104,
PhetZ 0.03, I
2Z 57%; Fig. 1) and AA with an increased
risk (ORAAZ 1.05, 95% CI: 1.02e1.07, PZ 1.7  104,
Phet Z 0.03, I
2 Z 56%). The association between one
standard deviation increase in each of the other PUFAs
defined by their respective IVs and CRC risk were null
(Supplementary Fig. 1).
Of the three SFAs studied, increased SA was nomi-
nally associated with CRC risk (ORSA Z 1.17, 95% CI:
1.01e1.35, P Z 0.041, Phet Z 0.04, I
2 Z 55%).
To formally assess the impact of heterogeneity on
study findings we derived ORs under a random-effects
Table 3
Odds ratios (ORs) and 95% confidence intervals (CI) for one standard deviation increase in genetically predicted plasma fatty acid levels and
colorectal cancer risk.
Fatty acid Significant associations
OR (fixed
effects)
95% CI
(fixed effects)
P-value
(fixed effects)
OR (random
effects)
95% CI
(random
effects)
P-value
(random
effects)
I2 Phet
Arachidic acid 0.92 0.61e1.39 0.7 0.93 0.61e1.40 0.71 3% 0.41
Palmitic acid (PA) 0.97 0.78e1.21 0.82 0.97 0.78e1.21 0.82 0% 0.47
Stearic acid (SA) 1.16 1.01e1.35 0.04 1.2 0.95e1.49 0.12 55% 0.04
Docosahexaenoic acid (DHA) 1.32 0.94e1.87 0.11 1.32 0.94e1.87 0.11 0% 0.65
Docosapentaenoic acid (DPA) 1.58 0.99e2.52 0.06 1.63 0.97e2.73 0.06 17% 0.3
Eicosapentaenoic acid (EPA) 0.39 0.13e1.21 0.1 0.39 0.13e1.21 0.1 0% 0.57
Arachidonic acid (AA) 1.05 1.02e1.07 1.7  104 1.05 1.02e1.09 4.9  103 56% 0.03
Dihomo-g-linolenic acid (DGLA) 0.91 0.83e1.00 0.06 0.95 0.80e1.01 0.07 23% 0.26
Linoleic acid (LA) 0.95 0.93e0.98 3.7  104 0.95 0.91e0.99 8.9  103 57% 0.03
Oleic acid (OA) 0.77 0.65e0.92 3.9  103 0.76 0.62e0.94 9.7  103 26% 0.23
Palmitoleic acid (POA) 0.36 0.15e0.84 0.018 0.32 0.10e1.07 0.06 47% 0.08
Phet, P-value for heterogeneity; I
2, proportion of the total variation due to heterogeneity; SFA, saturated fatty acid; PUFA, polyunsaturated fatty
acid; MUFA, monounsaturated fatty acid.
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model. Associations between AA, LA and OA and CRC
risk remained significant (Table 3).
We assessed the impact of possible classical pleio-
tropism on MR estimates using both IVW and MR-
Egger regression tests. There was no evidence for
violation of the standard IV assumptions used for MR
analysis, such as a dependence on confounders
(Table 4).
In the present analysis, we used the SNP rs102275 in
combination with other SNPs to generate a polygenic
risk score for SA, OA and POA, whereas rs174547,
which is in LD with rs102275 (r2 Z 1.0 and D0 Z 1.0),
was used for DPA, AA, DGLA and LA. Both SNPs
annotate the FADS2 gene. FADS2 is a rate-limiting
enzyme in the desaturation of LA to AA, and a-lino-
lenic acid into DHA and EPA (Fig. 2). These FAs are
precursors for prostaglandins and leukotrienes, which
are key mediators of the inflammatory response. In an
eQTL analysis rs174547 and rs102275 genotype were
shown to be strongly correlated with FADS2 expres-
sion across a range of different tissue types, including
blood (P Z 3.98  1029), normal colon
(P Z 1.65  1010) and CRC (P Z 2.07  105)
(Supplementary Table 1).
Fig. 1. Meta-analysis odds ratios (OR) for colorectal cancer per unit increase in genetic risk score (standard deviation of trait) for sig-
nificant fatty acid associations. (a) Oleic acid; (b) arachidonic acid; (c) stearic acid; (d) linoleic acid; (e) palmitoleic acid; I2: proportion of
the total variation due to heterogeneity. Boxes: OR point estimate; its area is proportional to the weight of the study. Diamond: overall
summary estimate, with confidence intervals given by its width. Vertical line: null value (OR Z 1.0).
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4. Discussion
While dietary fat intake has been associated with the
CRC risk, teasing out specific FA associations and their
mechanistic basis has proven to be challenging. A
number of observational studies have reported associa-
tions between serum levels of specific FAs with CRC
[28,29], supporting our findings.
A major strength of the MR strategy to identify
causal associations is that it is not influenced by recall
bias and confounding that can affect traditional obser-
vational studies. Nevertheless, a key assumption in MR
is that the variants used to generate genetic scores are
associated with the exposure being queried. Herein, we
only made use of SNPs associated with each FA at
genome-wide significance from hypothesis-free GWAS.
Furthermore, we only used data from individuals of
European descent so as to limit bias from population
stratification. Another central assumption in MR is that
variants are associated with CRC only through the
exposure and are not confounded by pleiotropy, which
would be revealed by a positive correlation between
increasing effect sizes in the IVs and CRC risk. While we
did not observe such relationship, we acknowledge that
IVs for a number of the FAs were solely based on only
one or two SNPs, preventing assessment by IVW and
MR-Egger analysis. One strategy to overcome this and
fully investigate any pleiotropy would be to measure FA
serum levels in correlation with CRC risk.
In this analysis, the same SNP (rs102275, or corre-
lated SNP rs174547) was used to make causal de-
ductions between multiple FAs and CRC risk.
Therefore, SNPs have been used each time assuming
that the exposure individually accounts for the disease
association. The genetic variant association with CRC
risk is consequently double-counted, in that the effect is
attributed to different FA exposures [30]. With such
vertical pleiotropism, single locus MR analyses cannot
robustly decipher which FA is primarily driving the
relationship with CRC risk. Such considerations have
not been addressed in previous studies of the relation-
ship between PUFAs and prostate cancer [31] or be-
tween branched-chain amino acids and diabetes [32].
While we did not demonstrate a causal association
between other FAs including several PUFAs, SFAs and
CRC risk, we acknowledge that our power to demon-
strate a relationship was limited. For example, with
respect to EPA: assuming the variance explained by the
alleles is 0.04%, based on epidemiological observational
study data, and a relative risk of 1.04 we had <10%
power to demonstrate a relationship [33].
Accepting these caveats we have provided support for
differing effects of OA, and u-6 PUFAs LA and AA on
CRC risk. Our findings broadly accord with the findings
from many of the published ecological and epidemio-
logical observational studies. Notably, increased levels
of AA contribute as a risk factor to CRC development
[34,35], while increased intake of olive oil, which is high
in OA, is associated with decreased risk [36]. A number
of epidemiological studies have provided evidence that a
Mediterranean diet, with a higher olive oil intake, is
associated with reduced CRC risk [36e38].
In the eQTL analysis, both rs102275 and rs174547
show evidence of cis-regulatory effects on FADS2
expression. Intriguingly, rs174547 has previously been
reported to have opposing effects on FADS2 and
FADS1 expression in CRC [39]. Collectively, these data
provide for relationship between diet, genotype, FA
metabolism and CRC risk through modulation of an
inflammatory response.
Even so, a biological basis for associations between
specific FAs and CRC risk remain to be established. It is
however, predicted a priori that within any FA class,
different members have different actions and effects.With
Table 4
IVW and MR-Egger test results for combined fatty acid instrumental variables.
Fatty acid
subtype
Fatty acid IVW MR-Egger
Slope Estimate (95% CI) P-value Estimate (95% CI) P-value
SFA Stearic acid (SA) 0.1 (0.33 to 0.64) 0.30 Intercept 0.68 (4.79 to 3.43) 0.28
Slope 4.10 (19.86 to 28.06) 0.27
u-3 PUFA Docosapentaenoic acid (DPA) 0.46 (2.32 to 3.23) 0.55 Intercept 0.09 (0.56 to 0.39) 0.26
Slope 2.01 (7.9 to 11.61) 0.23
Eicosapentaenoic acid (EPA) 0.59 (7.99 to 9.16) 0.54 Intercept 0.11 (N/A) e
Slope 2.2 (N/A) e
u-6 PUFA Arachidonic acid (AA) 0.04 (0.2 to 0.33) 0.29 Intercept 0.04 (N/A) e
Slope 0.02 (N/A) e
Dihomo-g-linolenic
acid (DGLA)
0.09 (2.48 to 2.29) 0.70 Intercept 0.25 (N/A) e
Slope 0.90 (N/A) e
Linoleic acid (LA) 0.05 (0.17 to 0.07) 0.22 Intercept 0.02 (0.64 to 0.67) 0.77
Slope 0.07 (0.81 to 0.68) 0.46
MUFA Palmitoleic acid (POA) 1.03 (2.64 to 0.58) 0.15 Intercept 0.11 (0.27 to 0.05) 0.12
Slope 3.13 (3.16 to 9.41) 0.21
CI, confidence interval; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; IVW, inverse variant
weighted. *FA traits with two IVs, preventing calculation of CIs and P-value.
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respect tou-6, evidence supports the inflammatory effects
for AA through COX-2 production of inflammatory me-
diators [40] including prostaglandin E2, which affect CRC
carcinogenesis [41e43]. This implies that diets high inAA,
such as meat or eggs, may lead to more inflammatory
compounds, which in turn may increase CRC risk. While
increasing dietary LA, an essential FA, might potentially
enrich tissues with AA due to their metabolic link [44], a
geneeenvironment interaction may exist to influence
colon FA content [45]. There is however, contradictory
evidence from studies that have associated LA with both
an increased [46] and decreased risk of CRC, possibly by
altering u-6 to u-3 FA ratios [47] or alternatively pro-
duction of reactive oxygen species [48]. The ability of
aspirin to irreversibly inhibit COX-1 and COX-2 and
therefore lower pro-inflammatory signals independent of
genotype anddiet, has thus proved an attractive option for
CRC chemoprevention [49].
Fig. 2. Pathway of fatty acids. Shown are the various fatty acids analysed, and the enzymes involved in their metabolism. COX: cyclo-
oxygenase, LOX: 5-lipoxygenase.
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In conclusion, irrespective of the biological basis of
associations between FAs and CRC risk our findings are
consistent with the observation that the dietary
composition of MUFAs in Mediterranean diets are risk
reducing, and that a pro-inflammatory diet are risk
increasing [50]. While we may not be at a stage where we
can justifiably advise individuals to alter their intake of
specific FAs to decrease the risk of developing CRC, it
seems the current guidelines to moderate total fat and
SFA consumption and increase unsaturated FA intake
is likely to be beneficial.
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